GRTSQ — Gritstone bio Share News
0.000.00%
Last trade - 00:00- $0.00m
- -$15.21m
- $16.34m
Gritstone bio up after update on cancer therapy trial data
Brief: Gritstone Announces Updated Overall Survival Results From Granite Phase 1/2 Study
Gritstone bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: Point72 Asset Management L.P. Reports 7.8% Passive Stake In Gritstone Bio Inc - SEC Filing
Gritstone Bio climbs after Piper Sandler starts coverage with 'overweight'
U.S. RESEARCH ROUNDUP-Aveo Oncology, Gritstone Bio, Y-Mabs Therapeutics
Gritstone bio Inc expected to post a loss of 41 cents a share - Earnings Preview
Gritstone bio up on promising data from COVID-19 vaccine study
Brief: Gritstone Bio Announces Private Placement Of $45 Million
Brief: Gritstone Presents Positive Results From Two Phase 1 Coral Studies
Brief: Gritstone To Host Data Update On Coral And Discuss Application Of Self-Amplifying mRNA (samRNA) In Infectious Diseases
Brief: Gritstone Presents Positive Initial Phase 2 Data In Late-Line Solid Tumor Patients Treated With Kras-Directed Immunotherapy (Slate) At ESMO 2022
U.S. STOCKS ON THE MOVE-Minerva, Cano Health, United Maritime
U.S. STOCKS ON THE MOVE-Minerva, Akili, Pharvaris
Gritstone slips after Goldman Sachs says 'sell'
Brief: Gritstone Appoints Dr. Lawrence “Larry” Corey To Its Board Of Directors
Brief: Gritstone Reports Second Quarter 2022 Financial Results And Provides Business Update
Brief: Gritstone Establishes Credit Facility For Up To $80 Mln With Hercules Capital And Silicon Valley Bank
Brief: Gritstone Announces Updated Overall Survival Results In Advanced Colorectal Cancer Patients From Phase 1/2 Study Of Granite And Trial In Progress Poster At ASCO